Metropolis Healthcare Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Volume-led beat with no price lever: Revenue grew ~17% YoY to ₹450 crores, from 10% patient volume growth, 11% test volume growth and richer mix, with no price increase taken in 18 months.
• Margins expanded 210 bps to 25.2%: Operating leverage from volume growth and efficiency programs more than offset the cost of advancing annual increments and integrating the lower-margin Core Diagnostics business.
• Core Diagnostics integration is paying off: The acquired loss-making asset is now in its final integration leg, North India revenue contribution has doubled to 18%, and the effective acquisition multiple would be approximately 10x EBITDA based on expected FY27 earnings.
• Network math is tightening: 300 low-productivity centers were rationalized while 300 new ones were added, and the center-to-lab ratio improved from 1:21 to 1:24, with a target of 1:30 by year-end.
• What to watch next quarter: Whether the 14%–15% full-year revenue guidance holds through unpredictable weather-driven demand, the pace of Core Diagnostics margin improvement from its ~8% level at the end of last quarter, and any signal on when management will next take a price increase.

Volume-Driven Performance Without Price

• The growth engine is pure volume and mix: 17% revenue growth was achieved with no price increase over the last 18 months, driven by 10% patient volume growth and 11% test volume growth, with the balance from richer product mix and improved realizations. The last price increase was January 2025, and management is not contemplating another in the near future.
• Realization improvement was organic: The 5%–6% realization growth in Q1 came entirely from mix shift toward higher-value products, with TruHealth growing at 21% and Specialty at 17%. CGHS price revision was a one-time industry benefit but contributed very little to Metropolis given its ~1% CGHS exposure.
• Q1 seasonality broke favorably: Q1 is usually not a strong quarter, but revenue sequentially increased ~6% QoQ. Management acknowledged some theories about possible overflow from Q4 but could not fully dissect the reason, noting that Q4 itself was not exceptionally strong.
• Weather unpredictability is the wildcard: Management cautioned that quarter-to-quarter seasonality is increasingly difficult to predict because climate change is altering disease patterns and testing demand, making the business heavily influenced by unpredictable weather conditions.

Shah: "Look, I think none of us have a crystal ball. The reality is climate change is changing everything for everybody. Weathers are unpredictable and our business is heavily influenced by weather. Conditions which then impact and create diseases and then require testing. It's quite difficult to predict."

Core Diagnostics Integration & North India Build-Out

• Integration is nearly complete: Core Diagnostics is in the final leg of integration one year post-acquisition, with the genomics portfolio doubling and becoming one of the fastest-growing Specialty segments. North India revenue contribution rose from single digits to 18%, making it the fastest-growing region at 19% YoY.
• The acquisition math is working: Core was acquired as a distressed, loss-making business at less than 2x revenue. Based on expected FY27 EBITDA, the effective acquisition multiple would be ~10x EBITDA, demonstrating value creation from disciplined acquisition and integration. Management expects Core margins to reach ~25% over 3–4 years from acquisition, moving up this year from the current ~8% level.
• Genomics was the strategic prize: Management chose to buy rather than build in genomics because while acquiring sequencing platforms is relatively straightforward, the real gestation period lies in building scientific expertise, R&D capabilities and the ability to accurately interpret complex genomic data.
• Agra and Dehradun acquisitions are tracking ahead: Both Scientific Pathology Agra and DAPIC Dehradun, consolidated toward the end of Q1, are performing ahead of plan on revenue growth and EBITDA.

Shah: "When we evaluated the build versus buy decision for genomics, we recognized that while acquiring sequencing platforms and equipment is relatively straightforward, the real gestation period in genomics lies in building scientific expertise, R&D capabilities and the ability to accurately interpret complex genomic data."

Network Expansion & Rationalization

• Gross additions continue at pace: 300 centers were added in Q1, taking the total to over 500 service centers added in the last 12 months, with operations now across 750 towns. The target is ~400–500 net center additions in FY27.
• Rationalization cleaned up the tail: ~300 low-productivity or quality-issue centers were knocked off after almost two years, a regular exercise conducted every 12–18 months. These centers had very low productivity, so the closures did not impact revenues. Some closures were also due to partners relocating or choosing to exit.
• Lab count is declining, and that is intentional: Lab numbers have been coming down over the last two quarters as overlapping Core Diagnostics labs were shut down post-acquisition. No further significant lab rationalization opportunity remains, and the lab expansion agenda has been halted for almost five quarters.
• Deepening, not widening: Management will not expand beyond the current 750 towns, choosing instead to deepen presence within those towns. The center-to-laboratory ratio improved from 1:21 to 1:24 and is on track to reach ~1:30 by year-end, improving capacity utilization and operating leverage.

Chemmenkotil: "Every year we take a call on how many of them are not really been productive for us, not worth to put our efforts and energy there. That's why we just knock them off."

Margin Trajectory & Operating Leverage

• 210 bps expansion despite headwinds: EBITDA margin expanded to 25.2%, driven by healthy volume-led operating leverage, disciplined cost management, and the laboratory transformation program covering platform standardization, vendor consolidation, automation and procurement efficiencies. This was achieved despite advancing annual employee increments from July to April and absorbing Core Diagnostics' relatively lower margin profile.
• Organic business drove the expansion: Organic business delivered healthy margin expansion both YoY and sequentially, even with the increment timing change and Core integration drag.
• The medium-term path is 27%–28%: Management guided to 100–150 bps of EBITDA margin improvement in FY27, with a medium-term target of 27%–28% over this year and the next year. The drivers are operating leverage from increasing productivity of existing and new centers, plus cost initiatives already taken. No further stress on margin is expected from new towns or new labs, since both expansion agendas are paused.
• Tier-2 and Tier-3 economics are not dilutive: Management stated that margin profiles in strong branded markets in smaller cities are fairly strong, so expanding to these markets does not mean margin deterioration.
• Core and TruHealth are expected to be EBITDA-accretive: Both portfolios are expected to contribute positively to EBITDA growth in the next phase, though management declined to provide specific incremental margin comparisons between regular and specialized test portfolios, citing wide variation across tests.

Specialty Diagnostics & Competitive Moat

• Specialty grew 17% YoY: Growth was supported by increasing adoption of advanced testing, deeper clinician engagement, and cross-selling of Core Diagnostics oncology and Super Specialty capabilities. Management aims to increase Specialty portfolio contribution to 45% from the current 40%.
• The moat is years deep, not equipment deep: Management emphasized that Specialty success cannot be built simply by adding new tests or investing in advanced equipment. It requires years of investment in scientific expertise, quality systems, clinical credibility, specialist relationships and a broad high-end test portfolio.
• B2B is predominantly Specialty: B2B grew 15% YoY, and most B2B business is Specialty because B2B customers such as smaller labs, hospitals and institutional business predominantly outsource specialized tests. This quarter's growth includes Core revenue in the base, unlike Q4 when Core was excluded from the denominator.
• Competitive intensity is normal, not irrational: Management observed no irrational competitive behavior. Many new entrants pursue volume at high servicing costs, reach ₹50–75 crores in revenue, then realize they are not making money and stagnate. Scaling profitably is the real challenge, requiring the right domain expertise, scale opportunities and the ability to build trust with doctors that generates full-price patients and Specialty tests.

Shah: "Specialty Diagnostics is an attractive segment, but it is not an automatic ride to win. Success cannot be built simply by adding new tests or investing in advanced equipment. It requires years of investment in scientific expertise, quality systems, clinical credibility, specialist relationships, and a broad high-end test portfolio."

TruHealth, B2C & Channel Dynamics

• B2C grew 18% YoY: Growth was balanced between mature centers and the ramp-up of centers added over the last year, with strength across own centers and Tier-2/3 markets. Rural centers grew 36%.
• TruHealth grew 22%: The portfolio has been expanded beyond pathology to include basic radiology, vital checks and consultations under one roof. Radiology-integrated wellness packages grew over 40%, and premium TruHealth packages grew over 50%. Management aims to increase TruHealth contribution to 45% from 40%.
• TruHealth traction is spreading to smaller towns: The sequence of maturation in a new center or town is Routine, then Semi-Specialty, then Specialty, then TruHealth. Significant headroom remains to build TruHealth in Tier-1 and Tier-2 towns, with Tier-3 and beyond just starting to gain traction.
• Predictive genomics for wellness is not ready: Management will not add genomics to TruHealth until the science behind predictive genomics for wellness is validated in India, which it currently is not.
• GLP-1 testing is early and hard to isolate: While Metropolis has created pre-GLP testing packages, doctors may write their own prescriptions rather than using packages, making it difficult to separate GLP-1-driven testing from other organic growth. It is still early days for this trend.

Guidance & Commitments

Key Metrics